Products
Raltitrexed is commercially available as a powder for the preparation of an infusion solution (Tomudex). It was approved in many countries in 1998.
Structure and properties
Raltitrexed (C21H22N4O6S, Mr = 458.5 g/mol) is an analog of folic acid.
Effects
Raltitrexed (ATC L01BA03) has cytotoxic properties. The effects are due to selective inhibition of the enzyme thymidylate synthase. The enzyme is involved in the synthesis of thymidine triphosphate, a component of DNA. Inhibition leads to cell death.
Indications
For palliative treatment of advanced colorectal cancer.
Dosage
According to the SmPC. The drug is administered as an intravenous infusion.
Contraindications
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include blood count abnormalities, gastrointestinal distress, poor appetite, skin rash, weakness, fever, and mucosal inflammation.
